Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4003892 | 1.00 | MEN1 (0.48) | MEN1KMT2AJAK2HCAR3PDGFRB | |
| SCHEMBL4000397 | 0.88 | MEN1 (0.44) | MEN1KMT2AJAK2PDGFRBMAPT | |
| SCHEMBL4717347 | 0.85 | HCAR3 (0.46) | MEN1KMT2AHCAR3PDGFRBMAPT | |
| SCHEMBL4008389 | 0.83 | ROCK1 (0.45) | MAP2K7 | |
| SCHEMBL16493544 | 0.82 | MAPT (0.42) | MEN1KMT2AJAK2HCAR3PDGFRB | |
| SCHEMBL16493542 | 0.82 | MAPT (0.42) | MEN1KMT2AJAK2HCAR3PDGFRB | |
| SCHEMBL4002272 | 0.81 | MEN1 (0.59) | MEN1KMT2AJAK2HCAR3MAPT | |
| SCHEMBL3999930 | 0.81 | MAPT (0.51) | MEN1KMT2AMAPT | |
| SCHEMBL3999937 | 0.81 | MAPT (0.51) | MEN1KMT2AMAPT | |
| SCHEMBL3998615 | 0.80 | MEN1 (0.58) | MEN1KMT2AJAK2HCAR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547779-B2 | Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | TNK2, ROCK1, ARHGDIB | MEN1 2478/4885KMT2A 1939/4885JAK2 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.